Literature DB >> 30724327

Update the Multimodal Treatment of ADHD (MTA): twenty years of lessons.

Beatriz Martínez-Núñez1, Javier Quintero2.   

Abstract

Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder1 and consists in a persistent pattern of inattention and / or hyperactivity - impulsivity that interferes with the functioning or development of the person who suffers from it. Because it is a disorder that is present since childhood, the treatment of these patients should be multimodal, and it should include doctors, therapists, teachers and parents2. The choice of a pharmacological treatment adjusted to the specific needs of the patient optimizes the results of the intervention programs. In 1997, the National Institute of Mental Health (NIMH) started the study of multimodal treatment of attention deficit hyperactivity disorder (MTA), and this constitutes a landmark in the history of treatment research in child psychopathology. MTA is the largest study of its kind ever undertaken. In the present article we intend to review the existing clinical evidence about the results of the MTA from the nineties to the current date.

Entities:  

Mesh:

Year:  2019        PMID: 30724327

Source DB:  PubMed          Journal:  Actas Esp Psiquiatr        ISSN: 1139-9287            Impact factor:   1.196


  2 in total

1.  Structural brain abnormalities in children and adolescents with comorbid autism spectrum disorder and attention-deficit/hyperactivity disorder.

Authors:  Yoshifumi Mizuno; Kuriko Kagitani-Shimono; Minyoung Jung; Kai Makita; Shinichiro Takiguchi; Takashi X Fujisawa; Masaya Tachibana; Mariko Nakanishi; Ikuko Mohri; Masako Taniike; Akemi Tomoda
Journal:  Transl Psychiatry       Date:  2019-12-09       Impact factor: 6.222

2.  Prevalence of multimodal treatment in children and adolescents with ADHD in Germany: a nationwide study based on health insurance data.

Authors:  Christian Bachmann; Oliver Riedel; Simon Klau; Ingo Langner; Oliver Scholle
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2021-12-18       Impact factor: 3.033

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.